Recent discussions highlight concerns about insurance companies implementing lifetime caps on GLP-1 therapy, specifically a two-year limit, which may lead to loss of health benefits as there is no evidence of a lasting legacy effect from these medications. Simultaneously, Medicare Part D is seeing increased restrictions on GLP-1 coverage amidst rising demand for obesity drugs. Contrary to some claims, experts argue that GLP-1 agonists could potentially prevent or slow the progression of chronic kidney disease. According to MIT's Jonathan Gruber, the financial implications of expanding coverage for these drugs are significant, with estimates suggesting a substantial cost to the US government.
At current prices, it would cost the US government a staggering sum to expand insurance coverage for GLP-1s, according to MIT’s Jonathan Gruber: https://t.co/1KMiFQlxRo #GSExchanges https://t.co/kwtZ6uFmZY
This week's @PharmaPinkSheet Monday feature ... #pinksheet #Pharma: GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows https://t.co/Ngn2heJ8NU
So people who don’t actually know the data on GLP-1 agonists talking about GLP-1 agonists. Seems legit. Btw none of these things are true. In fact these drugs may actually prevent chronic kidney disease / decrease progression. https://t.co/2H7kYUKPPF
Insurance companies are now placing lifetime (2 year) caps on GLP1 therapy. I wrote about the potential harm of this practice. There is no evidence the drugs provide a legacy effect; therefore health gains are likely lost. ⤵️ https://t.co/ji2laBcLqv
Thoughts about GLP1 medications https://t.co/0jOqqzCVtr